Multiplex Biomarker Scoring for PD-1 Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting patient response to PD-1 axis directed therapy are inconsistent due to limited predictive biomarkers and variable tumor microenvironment interactions, necessitating a more effective approach for identifying responsive patients.
Innovation Solution
A method involving multiplex affinity histochemical staining and image analysis to develop a scoring function that correlates biomarker features with treatment response, using features such as PD-L1, CD8, CD3, and LAG3 expression levels to predict patient response to PD-1 axis therapies like pembrolizumab and nivolumab.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If PD-L1 is used as the predictive biomarker for patient selection, then the approach is simple and widely applicable, but the predictive results are inconsistent and reliability is limited
Solution Approach 1:
The patent combines multiple biomarkers (PD-L1, PD-1, LAG-3, CD8, CD3, CD68) and their spatial relationships into a comprehensive scoring function. This merging of multiple indicators resolves the inconsistency of single biomarker prediction by capturing the complex interactions within the tumor microenvironment, thereby improving predictive reliability while maintaining clinical applicability.
Solution Approach 2:
The invention creates a composite scoring function that integrates multiple biomarker expressions and spatial configurations. This composite approach treats the prediction system as a multi-component material where each biomarker contributes to the overall predictive accuracy, resolving the trade-off between simplicity and reliability.
2Reliability
If multiple biomarkers and spatial arrangements are analyzed, then predictive accuracy is improved, but the complexity of the analysis increases
Solution Approach 1:
The patent segments the complex tumor microenvironment analysis into distinct functional components: identifying individual biomarker expressions (PD-L1, PD-1, LAG-3, CD8, CD3, CD68), calculating their spatial relationships, and computing a composite score. This segmentation allows the complex analysis to be performed systematically and reproducibly, managing complexity while improving accuracy.
Solution Approach 2:
The invention transforms qualitative biomarker expressions into quantitative parameters (expression levels, spatial distances, ratios) that can be processed by computational algorithms. This parameter transformation simplifies the analysis complexity by providing standardized inputs for the scoring function while maintaining high predictive accuracy.
3Reliability
If comprehensive biomarker panels are used, then the predictive capability is enhanced, but the cost and time for analysis increase
Solution Approach 1:
The patent performs preliminary actions by pre-defining the scoring function parameters and weightings based on training data. This allows the actual patient analysis to be performed more quickly using established algorithms, reducing analysis time while maintaining enhanced predictive capability through comprehensive biomarker evaluation.
Data Source
AI summary
A scoring functions is developed and used for identifying patients who might be responsive to a PD-1 axis directed therapy. The scoring functions are obtained by extracting features from multiplex-stained sections, selecting features that correlate with response to the therapy using a feature selection function, and fitting one or more of the selected features to a plurality of candidate scoring functions. A candidate scoring function showing the desired balance between predictive sensitivity and specificity may then selected for incorporation into a scoring system that includes at least an image analysis system.